Decoupling Behavioral Domains via Kynurenic Acid Analog Optimization: Implications for Schizophrenia and Parkinson’s Disease Therapeutics
Open accessPublished version of a preprint
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Kynurenic acid (KYNA), a putative neuroprotective agent, modulates glutamatergic pathways in schizophrenia and Parkinson’s disease but is limited by acute motor activity impairments (e.g., ataxia). Research leveraging animal disease models explores its structure–activity relationship to enhance therapeutic efficacy while mitigating adverse effects, addressing global neuropsychiatric disorders affecting over 1 billion people. Structural analogs of KYNA (SZR-72, SZR-73, and SZR-81) were designed to uncouple therapeutic benefits from motor toxicity; yet, systematic comparisons of their acute behavioral profiles remain unexplored. Here, we assess the motor safety, time-dependent effects, and therapeutic potential of these analogs in mice. Using acute intracerebroventricular dosing, we evaluated motor coordination (rotarod), locomotor activity (open-field), and stereotypic behaviors. KYNA induced significant ataxia and stereotypic behaviors at 15 min, resolving by 45 min. In contrast, all analogs avoided acute motor deficits, with SZR-73 maintaining baseline rotarod performance and eliciting a delayed decrease in ambulation and inquisitiveness in open-field assays. These findings demonstrate that the structural optimization of KYNA successfully mitigates motor toxicity while retaining neuromodulatory activity. Here, we show that SZR-73 emerges as a lead candidate, combining transient therapeutic effects with preserved motor coordination. This study advances the development of safer neuroactive compounds, bridging a critical gap between preclinical innovation and clinical translation. Future work must validate chronic efficacy, disease relevance, and mechanistic targets to harness the full potential of KYNA analogs in treating complex neuropsychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Disease and the Impact of Mental and Addictive Disorders
Rehm, J., & Shield, K. D. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-0997-0 · Cited by 1,388
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
A rotarod test for evaluation of motor skill learning
Shiotsuki, H., Yoshimi, K., Shimo, Y., Funayama, M., Takamatsu, Y., Ikeda, K., Takahashi, R., Kitazawa, S., & Hattori, N. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.03.026 · Cited by 627
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393 · cited 1×
“…study addresses these gaps by exploring kynurenic acid (KYNA) analogs, which modulate neuroinflammatory and glutamatergic pathways, as a novel strategy to balance efficacy and safety in a critical step toward alleviating the socioeconomic and humanistic toll of these debilitating disorders [20–24].”
Neuroimaging biomarkers for Alzheimer’s disease.
Márquez, F., & Yassa, M. A. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0325-5 · Cited by 289
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142 · cited 2×
“This intricate interplay positions KYNA as a pivotal mediator at the intersection of inflammation and resilience, making the KYN pathway a promising therapeutic target [27,39,47,48].”
Brain-targeted delivery shuttled by black phosphorus nanostructure to treat Parkinson's disease
Xiong, S., Li, Z., Liu, Y., Wang, Q., Luo, J., Chen, X., Xie, Z., Zhang, Y., Zhang, H., & Chen, T. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120339 · Cited by 113
Measuring behavior in the home cage: study design, applications, challenges, and perspectives
Grieco, F., Bernstein, B. J., Biemans, B., Bikovski, L., Burnett, C. J., Cushman, J. D., van Dam, E. A., Fry, S. A., Richmond-Hacham, B., Homberg, J. R., et al. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.735387 · Cited by 109
Tanaka, M. (2025) · doi:10.20944/preprints202412.0679.v2 · Cited by 42
Self-citationTanaka, M. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/197425 · Cited by 27 · cited 1×
“Only by integrating chronic safety data, mechanistic clarity, and disease complexity can KYNA analogs transition from promising preclinical candidates to viable therapies, ensuring their benefits withstand the multifaceted challenges of human neuropsychiatric care [128,129].”
Self-citationAdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis
Barbalho, S. M., Laurindo, L. F., de Oliveira Zanuso, B., da Silva, R. M. S., Gallerani Caglioni, L., Nunes Junqueira de Moraes, V. B. F., Fornari Laurindo, L., Dogani Rodrigues, V., da Silva Camarinha Oliveira, J., Beluce, M. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020484 · Cited by 18 · cited 1×
“Concurrently, KYNA modulates neuroimmune interactions, suppressing pro-inflammatory cytokine release (e.g., TNF-α , IL-6) and microglial activation, thereby attenuating chronic neuroinflammation linked to disorders such as multiple sclerosis and depression [27,39–43].”
Self-citation
Cited by
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Self-citationFrom Microbial Switches to Metabolic Sensors: Rewiring the Gut–Brain Kynurenine Circuit
Tanaka, M., & Vécsei, L. (2025) · doi:10.20944/preprints202506.0880.v1 · Cited by 24
Self-citationFrom Biomarkers to Behavior: Mapping the Neuroimmune Web of Pain, Mood, and Memory
Tanaka, M., & Battaglia, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092226 · Cited by 13
Self-citationTanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Self-citationNeurogenesis and Neuroinflammation in Dialogue: Mapping Gaps, Modulating Microglia, Rewiring Aging
Tanaka, M. (2026) · Cells · doi:10.3390/cells15010078 · Cited by 11
“Together, these approaches shrink the translational distance, allowing rodent mechanistic insights to be anchored in human relevance and opening new opportunities for therapeutic discovery [350,351].”
Self-citation
Metadata
- Authors
- Martos, D., Lőrinczi, B., Szatmári, I., Vécsei, L., & Tanaka, M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2025-06-25
- Volume
- 14
- Issue
- 13
- Pages
- 973
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4411618849
- Cited by
- 12
- References
- 12
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.